drugset
drugset / Trial / NCT00738621

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

NCT00738621 ↗

Phase 4 Completed 100 enrolled Scott and White Hospital & Clinic Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to compare the efficacy of the use of oral aprepitant in combination with intravenous ondansetron and dexamethasone with the efficacy provided by the use of oral aprepitant and dexamethasone for preventing vomiting during the first 24-48 hours after breast surgery.

Timeline

Start
2008-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 4 mg Intravenous
Comparator Aprepitant Other / unclassified 40 mg Oral
Comparator Dexamethasone Small molecule 4 mg Intravenous

Indications

No indication recorded.